Bayer takes pre-emptive strike to protect haemophilia treatment
31-08-2017
Xesai / iStockphoto.com
A US jury has ordered pharmaceutical company Baxalta Inc. to pay $155 million to Bayer Healthcare following a patent infringement trial.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Bayer Healthcare, Baxalta Inc., Takeda Pharmaceutical Company, Factor VIII conjugates, haemophilia, patent infringement, patent licensing
